MedTrace Logo

Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus

NCT00057317 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2016-08-24

No results posted yet for this study

Summary

The objective of the study is to determine the dose(s) of Ro 205-2349 which, when compared to placebo, are efficacious, safe and tolerable in improving glycemic control in patients with type 2 diabetes. Doses of 5 to 20 mg/day will be studied.

Conditions

Interventions

DRUG

Ro 205-2349

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-12-31
Primary Completion
2003-12-31
Completion
2003-12-31

Countries

  • United States
  • Bulgaria
  • Canada
  • Estonia
  • Latvia
  • Lithuania
  • Mexico
  • Panama
  • Puerto Rico
  • Romania
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00057317 on ClinicalTrials.gov